After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets

As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion.

Raccontata damorningstar.comendpoints.newspharmaceutical-technology.com